Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: Age And Outcome Duration Cloud Innovative Therapy Reimbursement

$1m-Plus For Gene And Cellular Therapies Hard To Swallow When Patients’ Responses Differ

Executive Summary

Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.

You may also be interested in...

BioMarin’s Hemophilia Gene Therapy Still Works After Four Years, But Effects Tail Off

Latest results show a show decline in effects, but still offers freedom from injections with almost no bleeds recorded in 13 patients.

Sarepta’s Gene Therapy Impresses In Limb-Girdle Muscular Dystrophy

Positive functional results from Sarepta’s SRP-9003 gene therapy in limb-girdle muscular dystrophy type 2E bodes well for a pivotal study, and for the company’s studies of other potential gene therapies in Duchenne muscular dystrophy.

Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts